Save up to 90% on Columvi with Coupons, Discount Cards & Patient Assistance Programs

Columvi is the brand name for glofitamab-gxbm IV infusion.

Columvi is available as a 2.5 mg/2.5 mL (1 mg/mL) or 10 mg/10 mL (1 mg/mL) single-dose vial.

Columvi is a monoclonal antibody used to treat lymphoma.

Columvi works by helping your immune system slow or stop the spread of cancer cells.

Columvi is an IV infusion given by your care team in a hospital or clinic setting.
Your first cycle is given as follows:
Day 1 Obinutuzumab 1,000 mg
Day 8 Step-up dose 1 2.5 mg
Day 15 Step-up dose 2 10 mg
Cycle 2-12: Day 1 30 mg

Columvi is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

• Common side effects of Columvi:
• Bone pain
• Constipation
• Diarrhea
• Fatigue
• Muscle pain
• Skin rash

Serious side effects are rare with Columvi. Side effects that you should report to your care team as soon as possible:

Allergic reactions—skin rash, itching, hives, swelling of the face, lips, tongue, or throat
Fever, chills, unusual weakness or fatigue, loss of appetite, nausea, headache, dizziness, feeling faint or lightheaded, shortness of breath, fast or irregular heartbeat, which may be signs of cytokine release syndrome
Infection—fever, chills, cough, sore throat, wounds that don’t heal, pain or trouble when passing urine, general feeling of discomfort or being unwell
Low red blood cell level—unusual weakness or fatigue, dizziness, headache, trouble breathing
Pain, tingling, or numbness in the hands or feet, muscle weakness, change in vision, confusion or trouble speaking, loss of balance or coordination, trouble walking, seizures
Swelling and pain of the tumor site or lymph nodes
Unusual bruising or bleeding

• The following medications may interact with Columvi:
• For certain CYP substrates where minimal concentration changes may lead to serious adverse reactions
• monitor for toxicities or drug concentrations of such CYP substrates when coadministered with Columvi.

Genentech, Inc.

Columvi may harm your unborn baby.
Females who are able to become pregnant:
Your healthcare provider should do a pregnancy test before you start treatment with Columvi.
You should use effective birth control (contraception) during treatment and for 1 month after your last dose of Columvi. Talk to your healthcare provider about what birth control method is right for you during this time.
Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Columvi.

• Glofitamab-Gxbm